Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
AI Guidelines for Physicians
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Please select the option that best describes you:
Topics:
Endocrinology
•
Thyroid Disorders
Do you avoid the use of beta blockers when treating hyperthyroidism in patients with well controlled asthma or COPD?
Related Questions
Is there a role for increasing dietary vitamin E in patients at risk for developing autoimmune thyroiditis?
Is it safe to discontinue prenatal vitamins that contain biotin for a few days during pregnancy when labs in particular thyroid tests are planned for treating hypo or hyperthyroidism in pregnancy?
For patients on T4/T3 combination therapy for management of hypothyroidism is there an indication for monitoring T3 levels and if so, what is the appropriate timing (trough versus peak) given the pharmacokinetics of liothyronine?
What doses of methimazole do you consider "low dose" when treating Graves' disease long-term?
Do you recommend low dose RAI ablation for low risk papillary thyroid cancer with lymphatic invasion alone (no angio-invasion or known nodal involvement)?
Does the degree of TSH suppression significantly impact the risk of differentiated thyroid carcinoma recurrence?
Do you recommend prescribing methimazole to prevent iodinated contrast media-induced exacerbation of thyrotoxicosis in patients with pre-existing hyperthyroidism?
Would you recommend pharmacologic treatment with levothyroxine for a patient with subclinical hypothyroidism and CAD s/p stent placement even if the TSH is less than 10mIU/L, given a described association with reduced risk for major adverse cardiovascular events with treatment?
Given the newer ATA guidelines, what is your approach to the management of Hurthle cell carcinoma?
Does solid/trabecular type papillary thyroid carcinoma pathology confer a higher risk of recurrence and warrant radioactive iodine ablation therapy?